aTyr Pharma to Present at March Investor Conferences
February 25 2021 - 8:00AM
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel biological pathways, today announced that it will present at
four virtual investor conferences in March.
Sanjay S. Shukla, M.D., M.S., President and
Chief Executive Officer, will present a corporate overview at the
H.C. Wainwright Global Life Sciences Conference, the 33rd Annual
ROTH Conference, the Oppenheimer 31st Annual Healthcare Conference
and the Maxim Group Emerging Growth Virtual Conference. Dr. Shukla
will also participate in a panel on immuno-oncology targets at the
ROTH Conference.
Details of the events are as follows:
Conference: H.C. Wainwright Global Life Sciences ConferenceDate:
March 9-10, 2021Presentation Time: On Demand
Conference: 33rd Annual ROTH ConferenceDate: March 15-17,
2021Presentation Time: On Demand Panel Title: Novel Immuno-Oncology
Targets That Could Improve Clinical OutcomesPanel Date: March 15,
2021Panel Time: 2:00 p.m. Eastern Time
Conference: Oppenheimer 31st Annual Healthcare ConferenceDate:
March 17, 2021Presentation Time: 1:10 p.m. Eastern Time
Conference: Maxim Group Emerging Growth Virtual ConferenceDate:
March 17-18, 2021Presentation Time: On Demand
The presentations and panel will be available
for registered attendees of each conference to view. Following the
events, a replay of select presentations will be available on the
Investor’s section of the company’s website at
www.atyrpharma.com.
About aTyr
aTyr is a biotherapeutics company engaged in the
discovery and development of innovative medicines based on novel
biological pathways. aTyr’s research and development efforts are
concentrated on a newly discovered area of biology, the
extracellular functionality and signaling pathways of tRNA
synthetases. aTyr has built a global intellectual property estate
directed to a potential pipeline of protein compositions derived
from 20 tRNA synthetase genes and their extracellular targets.
aTyr’s primary focus is ATYR1923, a clinical-stage product
candidate which binds to the Neuropilin-2 receptor and is designed
to down-regulate immune engagement in inflammatory lung diseases.
For more information, please visit http://www.atyrpharma.com.
Contact: |
Ashlee Dunston |
Director, Investor Relations and
Corporate Communications |
adunston@atyrpharma.com |
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2023 to Apr 2024